MoonLake Immunotherapeutics Announces the Publication of New Long-Term Disease Control Data from a Phase IIb Psoriasis Trial of the Nanobody^® Sonelokimab

MoonLake Immunotherapeutics announced that the British Journal of Dermatology (BJD) has published a new data analysis, which can be accessed in the BJD online library, from the Phase IIb clinical trial assessing the effect of sonelokimab on moderate to severe plaque type psoriasis over 48 weeks.